NCT00400686 · OUTCOME

Number of Patients With an at Least 2gm/dL Increase in Hgb

Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma · Source last updated 2018-02-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: participants
Interval / dispersion: Not reported
Time frame: Baseline to Day 28

Groups in this outcome

Epoetin Alfa - 80,000 U sc

Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels epoetin alfa: Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Epoetin Alfa - 80,000 U sc	31

Reported measurements

Source class 1

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Epoetin Alfa - 80,000 U sc	9	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
9

denoms

counts
group Id
OG000
value
31
units
Participants

groups

description
Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels epoetin alfa: Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.
id
OG000
title
Epoetin Alfa - 80,000 U sc

param Type

NUMBER

reporting Status

POSTED

time Frame

Baseline to Day 28

title

Number of Patients With an at Least 2gm/dL Increase in Hgb

type

PRIMARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice